Kiniksa Pharmaceuticals International is a biopharmaceutical firm that develops and sells drugs addressing inflammatory conditions across the U.S., U.K., and other markets. The company markets ARCALYST for recurrent pericarditis and cardiac sarcoidosis, and is advancing KPL-387, an experimental antibody in mid-stage trials for the same indication, along with an earlier-stage candidate called KPL-116. Founded in 2015 and headquartered in London, the company rebranded from its original name in mid-2024.

entry readiness 0 · NOT READY · exit proximity 58

Value area 60.77–98.48 · 4% of 120d volume overhead · clean runway